Sex differences in treatment response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitor: a cohort study from the DANBIO registry
An erratum to this article was published (Scand J Rheumatol, Sep 2025 ↗)
Main finding · Good responseResult — go to the resultAdjusted relative risk 1.14 95% CI 1.06–1.23Authors' conclusion
Despite similar baseline disease activity, females had a lower chance than males of achieving good response 4 and 12 months after starting treatment with first TNFi.
Study context
- Population
- Danish rheumatoid arthritis (RA) patients starting their first tumour necrosis factor inhibitor (TNFi) treatment between 2006 and 202275% females
- Participants
- 7,789 patients
- Exposure
- Males vs females with RA initiating first TNFi
- Outcome
- Treatment response (good response) and persistence by sex
- Follow-up
- 4 and 12 months
Methodological detailsnationwide, registry-based (DANBIO)
- Nationwide
- Registry-based (DANBIO)
Main finding
Good response · 12 months
Adjusted relative risk
1.14
95% CI 1.06–1.23
By group
Malesvs Females
adjusted RR 1.14 (95% CI 1.06–1.23)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR for treatment termination (95% CI) | |
|---|---|---|
| Treatment termination within first year | 0.82 (0.73–0.92) | |
| 0.512AHR for treatment termination (log scale) |
Median treatment persistence, age <50 years (subgroup)
ΔDAS28-CRP · 12 months
- Females had slightly smaller ΔDAS28-CRP than males, mainly due to less reduction of swollen joint count (SJC) and CRP
Treatment persistence, age >50 years (subgroup)
- The same difference was not seen in patients aged > 50 years
Original publication
Sex differences in treatment response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitor: a cohort study from the DANBIO registry. Scand J Rheumatol. Published 20 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →